Insulin icodec

Quote

anonymous

Guest
Have any rumors started circling about insulin icodec? Internet says file with the FDA h1 2023, launch h2 2023, I'm just wondering if y'all had heard any rumors about launch plans? Ie will you be hiring?
 




anonymous said:
Have any rumors started circling about insulin icodec? Internet says file with the FDA h1 2023, launch h2 2023, I'm just wondering if y'all had heard any rumors about launch plans? Ie will you be hiring?
Click to expand...
Nothing has been mentioned beyond possible FDA activity, best bet is to keep an active search alert for FDA and other news updates.
 




anonymous said:
Have any rumors started circling about insulin icodec? Internet says file with the FDA h1 2023, launch h2 2023, I'm just wondering if y'all had heard any rumors about launch plans? Ie will you be hiring?
Click to expand...

CP is a great place to come for information like this. Most companies really love it when they’re employees speculate on FDA approval and discuss large plans on a public forum.
 












anonymous said:
Correct, which is my point. You’ve come to absolutely the wrong place to find out “useful” information. I’m hoping your network is stronger than the anonymous folks on CP. But, I’m guessing not.
Click to expand...


Actually I think I'm in the right place... I'm just talking to the wrong guy.

Wheel of fortune and Jeopardy are over... So take your centrum silver and hit the hay papaw... So the non boomers can talk K?
 
















anonymous said:
Have any rumors started circling about insulin icodec? Internet says file with the FDA h1 2023, launch h2 2023, I'm just wondering if y'all had heard any rumors about launch plans? Ie will you be hiring?
Click to expand...
Guessing you’re an analyst looking for inside info? There are no rumors about an expansion, no.

I’m not an executive, but there are thousands of diabetes reps. My guess is that they will use what they already have to promote it or else contract it out. They won’t expand a sales force that’s already bloated.

That’s just a guess, though.
 




x2. Can't imagine there would be an expansion, more likely a shift in priority for certain reps. If you are truly looking for a career here, go ahead and apply before any of that happens!
 




anonymous said:
Guessing you’re an analyst looking for inside info? There are no rumors about an expansion, no.

I’m not an executive, but there are thousands of diabetes reps. My guess is that they will use what they already have to promote it or else contract it out. They won’t expand a sales force that’s already bloated.

That’s just a guess, though.
Click to expand...


Not an analyst... But if I was I know the last place to look for reliable insider info to base a trade off of would be sales reps.

I just assumed this was a pretty important launch and people would be talking. I sold apidra lantus and then toujeo for a while and selling insulin was just a fun gig. A once weekly insulin seemed like it would be a fun product to sell.


But it seems like I know more about the product than most of the commenters.
 




It will be a good product. With insulin pricing now not sure how good for the company. Reality is, majority of type 2s don’t need insulin and type 1 market novo has all but abandoned anyway.

Look for icosema to potentially have more of an impact. But that will yet to be determined. Look what happened with Xultophy.
 




anonymous said:
Not an analyst... But if I was I know the last place to look for reliable insider info to base a trade off of would be sales reps.

I just assumed this was a pretty important launch and people would be talking. I sold apidra lantus and then toujeo for a while and selling insulin was just a fun gig. A once weekly insulin seemed like it would be a fun product to sell.


But it seems like I know more about the product than most of the commenters.
Click to expand...
Sold. Past tense. The insulin market (and really entire diabetes market) is highly commoditized now and companies are rebating upwards of 70-80% on insulins. Even a novel insulin like this is going to have to be priced aggressively in order to secure coverage and thus the profitability calculus is not there to support an expansion. It’s likely E reps would carry it in their bag along with all the other newer insulins that are no longer promotes (like fiasp).

But please do pop off some more about how you know so much.
 




anonymous said:
It will be a good product. With insulin pricing now not sure how good for the company. Reality is, majority of type 2s don’t need insulin and type 1 market novo has all but abandoned anyway.

Look for icosema to potentially have more of an impact. But that will yet to be determined. Look what happened with Xultophy.
Click to expand...
There are too many generic options and novo would never price it right anyway. Don’t count on this saving the company or creating a job. It will flop like tresiba and xultophy did. I’m not really sure why they are wanting to stay in the branded insulin business. I guess they have enough money to waste.
 




anonymous said:
Not an analyst... But if I was I know the last place to look for reliable insider info to base a trade off of would be sales reps.

I just assumed this was a pretty important launch and people would be talking. I sold apidra lantus and then toujeo for a while and selling insulin was just a fun gig. A once weekly insulin seemed like it would be a fun product to sell.


But it seems like I know more about the product than most of the commenters.
Click to expand...

Maybe it is because some don't want to disclose internal company info to you. Insulin sales might have been a fun gig before glp1s came on the market, I would not want to be in that space.
 




anonymous said:
Not an analyst... But if I was I know the last place to look for reliable insider info to base a trade off of would be sales reps.

I just assumed this was a pretty important launch and people would be talking. I sold apidra lantus and then toujeo for a while and selling insulin was just a fun gig. A once weekly insulin seemed like it would be a fun product to sell.


But it seems like I know more about the product than most of the commenters.
Click to expand...

Actually, you don’t seem to know anything, so you’re on CP, of all places, begging for information.
 




Talk to your ram or MSL. They tell you what they not telling us yet.
no better A1c than lantus or tresiba. same hypo. weekly convenience but payers don't pay for that. Competing with 2 generic basals. Insulins are a money pit since they're rebated so much compared to GLP1 or obesity
 




anonymous said:
Talk to your ram or MSL. They tell you what they not telling us yet.
no better A1c than lantus or tresiba. same hypo. weekly convenience but payers don't pay for that. Competing with 2 generic basals. Insulins are a money pit since they're rebated so much compared to GLP1 or obesity
Click to expand...

You may/may not realize that most insulin trials are treat to target, so glycemic control should generally be similar, particularly with the analog basals. We look at secondary outcomes, hypo, TIR. ... This is like going back some years and arguing against the QW glp1RAs vs lira. I agree with you about US payors, and the main reason we pulled back on Xult which is a fantastic product.
 




anonymous said:
You may/may not realize that most insulin trials are treat to target, so glycemic control should generally be similar, particularly with the analog basals. We look at secondary outcomes, hypo, TIR. ... This is like going back some years and arguing against the QW glp1RAs vs lira. I agree with you about US payors, and the main reason we pulled back on Xult which is a fantastic product.
Click to expand...

Yes, you learn that in the first 2 weeks of initial sales training. That’s why the poster mentioned both A1c and hypos. What point are you trying to make? Was this another attempt to show us how brilliant you are? It didn’t work.
 




Top Bottom
Back
Quote